BrightSpring Health Services, Inc. Common Stock (BTSG) Cash Flow Statement

The wide swings in conversion suggest that reported net income is heavily influenced by non-cash items and working capital timing rather than steady operating earnings. Quarters with conversion above 3x, such as 2024Q4 and 2025Q1, appear to reflect collections of previously accrued receivables rather than durable earning power. Investors should monitor whether conversion normalizes toward 1.0x over full years, since sustained divergence would warrant scrutiny of accrual quality.

The recent FCF inflection is substantial, but it follows several quarters of near-zero or negative output, so the trend may not yet be established. The latest quarter's strength relies heavily on a $25.4M working capital inflow and low capex, which may not repeat. Based on the data, the trajectory appears improving but warrants confirmation over additional reporting periods before being treated as structural.

Capex consistently trailing D&A suggests the company is spending less on asset replacement than its amortization charges imply, which may flatter near-term free cash flow. Much of the D&A likely reflects acquired intangibles from the PharMerica transaction rather than physical asset depreciation, so the gap may be less concerning than it appears. Investors should monitor whether underinvestment in clinical or pharmacy infrastructure begins to constrain service capacity.

The magnitude of these swings relative to quarterly net income suggests that cash generation is highly sensitive to collection timing, which is consistent with Medicaid and payer reimbursement complexity. The 2026Q2 outflow coinciding with a sharp OCF drop to $43.9M implies that a single quarter of collection delay can erase most of the period's earnings contribution. Investors should track days sales outstanding closely, as persistent reversals would undermine confidence in reported cash conversion.

Acquisition spending has consumed a meaningful share of free cash flow, which suggests capital is being prioritized toward consolidation rather than balance sheet repair or shareholder returns. The buybacks, though modest relative to acquisition outlays, may signal management confidence but could also be offsetting dilution from equity compensation. The return on these acquisitions remains unproven in the supplied data, warranting further investigation.